Document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): December 11, 2016
|
|
Bellerophon Therapeutics, Inc. |
(Exact Name of Registrant as Specified in Charter)
|
| | |
Delaware | 001-36845 | 47-3116175 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
|
| |
184 Liberty Corner Road, Suite 302 Warren, New Jersey | 07059 |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (908) 574-4770
|
|
|
(Former Name or Former Address, if Changed Since Last Report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Departure of Matthew Holt
On December 11, 2016, Matthew Holt notified Bellerophon Therapeutics, Inc. (the “Company”) that he will resign as a director of the Company effective immediately. Mr. Holt’s decision was not a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Mr. Holt served as a director of the Company since February 2014.
Election of Fabian Tenenbaum
Effective December 11, 2016, the Board of Directors of the Company elected Fabian Tenenbaum, the Company’s current Chief Executive Officer, as a director.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
| | | | | | |
| | | | | | |
| | | | BELLEROPHON THERAPEUTICS, INC. |
| | | |
Date: December 12, 2016 | | | | By: | | /s/ Fabian Tenenbaum |
| | | | | | Name: Fabian Tenenbaum Title: Chief Executive Officer |